Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 11 » Issue 1

A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD

Authors Miravitlles M, Montero-Caballero J, Richard F, Santos S, García-Rivero JL, Ortega F, Ribera X

Received 25 June 2015

Accepted for publication 10 December 2015

Published 26 February 2016 Volume 2016:11(1) Pages 407—415

DOI https://doi.org/10.2147/COPD.S91118

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Charles Downs

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Marc Miravitlles,1 Jéssica Montero-Caballero,2 Frank Richard,2 Salud Santos,3 Juan Luis Garcia-Rivero,4 Francisco Ortega,5 Xavier Ribera6

1Pneumology Department, Hospital Universitari Vall d’Hebron, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 2Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; 3Pulmonology Department, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 4Pneumology Department, Hospital de Laredo, Cantabria, Spain; 5Pneumology Department, Hospital Virgen del Rocío, Sevilla, Spain; 6Boehringer Ingelheim Pharma GmbH & Co KG, Barcelona, Spain

Abstract: Delivery of inhaled medications via an inhaler device underpins the effectiveness of treatment for patients with chronic obstructive pulmonary disease (COPD). Correct inhaler technique among patients is also a predictor of achieving treatment compliance and adherence. Reporting of patient satisfaction with inhalers is therefore gaining increasing attention and is now recognized as an important patient-reported outcome in clinical trials involving patients with COPD or asthma. In this cross-sectional study, we use the validated Patient Satisfaction and Preference Questionnaire (PASAPQ) to assess the handling and satisfaction for Respimat® Soft Mist™ Inhaler (SMI) compared with the Breezhaler® dry powder inhaler (DPI) among patients with COPD in Spain. Patients were already assigned to therapy with either SPIRIVA® (tiotropium) Respimat® or with Hirobriz®/Onbrez®/Oslif® (indacaterol) Breezhaler® for at least 3 but not more than 6 months before completing the PASAPQ at a single visit to the study site. The primary endpoint of the trial was the mean total PASAPQ score. Secondary endpoints were the performance score domain of the PASAPQ, the convenience score domain of the PASAPQ, and the overall satisfaction score of the PASAPQ. For the primary endpoint, the mean PASAPQ total score in the Respimat® and Breezhaler® groups was 80.7 and 79.9, respectively (difference of 0.8, 95% confidence interval [CI] −2.9 to 4.5; P=0.67). The mean total performance scores were 82.5 and 78.2 (difference of 4.3, 95% CI −0.3 to 8.9; P=0.06), and the mean total convenience scores were 78.6 and 81.9 (difference of −3.3, 95% CI −7.0 to 0.4; P=0.08) for the Respimat® and Breezhaler® groups, respectively. Patients gave the Respimat® SMI and the Breezhaler® DPI overall satisfaction PASAPQ scores of 6.0 and 5.9, respectively, which shows that patients were satisfied with these inhalers.

Keywords: COPD, Respimat®, Breezhaler®, inhaler, handling

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment

Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I, Ovcharenko S, Shmelev E, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:183-187

Published Date: 8 January 2018

Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique

Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, Soriano JB, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:57-67

Published Date: 21 December 2017

Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency

Esquinas C, Janciauskiene S, Gonzalo R, Mas de Xaxars G, Olejnicka B, Belmonte I, Barrecheguren M, Rodríguez E, Nuñez A, Rodríguez-Frías F, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3381-3390

Published Date: 29 November 2017

Palliative care and prognosis in COPD: a systematic review with a validation cohort

Almagro P, Yun S, Sangil A, Rodríguez-Carballeira M, Marine M, Landete P, Soler-Cataluña JJ, Soriano JB, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1721-1729

Published Date: 9 June 2017

Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide

Blanco I, Bueno P, Diego I, Pérez-Holanda S, Lara B, Casas-Maldonado F, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1683-1694

Published Date: 8 June 2017

Bronchiectasis in COPD patients: more than a comorbidity?

Martinez-Garcia MA, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1401-1411

Published Date: 11 May 2017

Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics

Ramon MA, Esquinas C, Barrecheguren M, Pleguezuelos E, Molina J, Quintano JA, Roman-Rodríguez M, Naberan K, Llor C, Roncero C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1173-1181

Published Date: 13 April 2017

Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update

Blanco I, Bueno P, Diego I, Pérez-Holanda S, Casas-Maldonado F, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:561-569

Published Date: 13 February 2017

Diagnosis of alpha-1 antitrypsin deficiency: a population-based study

Barrecheguren M, Monteagudo M, Simonet P, Llor C, Rodriguez E, Ferrer J, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:999-1004

Published Date: 10 May 2016

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

Miravitlles M, Gáldiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:123-132

Published Date: 18 January 2016

The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD

Miravitlles M, García-Sidro P, Fernández-Nistal A, Buendía MJ, Espinosa de los Monteros MJ, Esquinas C, Molina J

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2571-2579

Published Date: 30 November 2015

Is a previous diagnosis of asthma a reliable criterion for asthma–COPD overlap syndrome in a patient with COPD?

Barrecheguren M, Román-Rodríguez M, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1745-1752

Published Date: 1 September 2015

What pulmonologists think about the asthma–COPD overlap syndrome

Miravitlles M, Alcázar B, Alvarez FJ, Bazús T, Calle M, Casanova C, Cisneros C, de-Torres JP, Entrenas LM, Esteban C, García-Sidro P, Cosio BG, Huerta A, Iriberri M, Izquierdo JL, López-Viña A, López-Campos JL, Martínez-Moragón E, Pérez de Llano L, Perpiñá M, Ros JA, Serrano J, Soler-Cataluña JJ, Torrego A, Urrutia I, Plaza V

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1321-1330

Published Date: 15 July 2015

Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease

Miravitlles M, Huerta A, Valle M, García-Sidro P, Forné C, Crespo C, López-Campos JL

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:367-377

Published Date: 16 February 2015

Caregivers’ burden in patients with COPD

Miravitlles M, Peña-Longobardo LM, Oliva-Moreno J, Hidalgo-Vega Á

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:347-356

Published Date: 12 February 2015

The concept of control of COPD in clinical practice

Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1397-1405

Published Date: 12 December 2014

Geographic differences in clinical characteristics and management of COPD: the EPOCA study

Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:803-814

Published Date: 5 December 2008

Readers of this article also read:

Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation

Santos S, Marin A, Serra-Batlles J, de la Rosa D, Solanes I, Pomares X, López-Sánchez M, Muñoz-Esquerre M, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:515-525

Published Date: 11 March 2016

COPD assessment test and severity of airflow limitation in patients with asthma, COPD, and asthma–COPD overlap syndrome

Kurashima K, Takaku Y, Ohta C, Takayanagi N, Yanagisawa T, Sugita Y

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:479-487

Published Date: 4 March 2016

Determinants of successful completion of pulmonary rehabilitation in COPD

Brown AT, Hitchcock J, Schumann C, Wells JM, Dransfield MT, Bhatt SP

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:391-397

Published Date: 25 February 2016

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations

Calverley PM, Postma DS, Anzueto AR, Make BJ, Eriksson G, Peterson S, Jenkins CR

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:381-390

Published Date: 25 February 2016

Development of a spirometry T-score in the general population

Lee SW, Kim HK, Baek S, Jung JY, Kim YS, Lee JS, Lee SD, Mannino DM, Oh YM

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:369-379

Published Date: 23 February 2016

Mortality and economic burden of Krasnoyarsk region, Russia, caused by regular tobacco usage

Artyukhov IP, Arshukova IL, Dobretsova EA, Shulmin AV

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:351-355

Published Date: 22 February 2016

Self-management of health care behaviors for COPD: a systematic review and meta-analysis

Jolly K, Majothi S, Sitch AJ, Heneghan NR, Riley RD, Moore DJ, Bates EJ, Turner AM, Bayliss SE, Price MJ, Singh SJ, Adab P, Fitzmaurice DA, Jordan RE

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:305-326

Published Date: 17 February 2016

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

Miravitlles M, Gáldiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:123-132

Published Date: 18 January 2016